138 related articles for article (PubMed ID: 19112767)
1. Severe erythroderma in a patient under intermittent therapy with efalizumab.
Hernandez Garcia I
J Drugs Dermatol; 2008 Oct; 7(10):987-9. PubMed ID: 19112767
[TBL] [Abstract][Full Text] [Related]
2. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study.
Gisondi P; Giglio MD; Girolomoni G
J Dermatolog Treat; 2006; 17(3):172-5. PubMed ID: 16854760
[TBL] [Abstract][Full Text] [Related]
3. Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment.
Kop EN; Körver JE; Van Ruysevelt D; De Jong EM; Van der Valk PG; Van de Kerkhof PC
J Dermatolog Treat; 2009; 20(1):67-9. PubMed ID: 18651300
[TBL] [Abstract][Full Text] [Related]
4. Efalizumab-induced thrombocytopenia: report of relapse after re-administration.
Kiorpelidou D; Tsiouri G; Gaitanis G; Akritidis N; Bassukas ID
Clin Exp Dermatol; 2009 Dec; 34(8):e914-6. PubMed ID: 20055866
[TBL] [Abstract][Full Text] [Related]
5. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
Wozel G; Vitéz L; Meurer M
Acta Dermatovenerol Alp Pannonica Adriat; 2008 Sep; 17(3):133-6. PubMed ID: 18853077
[TBL] [Abstract][Full Text] [Related]
6. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
[TBL] [Abstract][Full Text] [Related]
7. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
Lewis TG; Tuchinda C; Lim HW; Wong HK
J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
[TBL] [Abstract][Full Text] [Related]
8. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
Papp KA; Toth D; Rosoph L
BMC Dermatol; 2006 Oct; 6():9. PubMed ID: 17067371
[TBL] [Abstract][Full Text] [Related]
9. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
de Groot M; de Rie MA; Bos JD
Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
[No Abstract] [Full Text] [Related]
10. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
Heikkilä H; Ranki A; Cajanus S; Karvonen SL
Arch Dermatol; 2005 Dec; 141(12):1607-10. PubMed ID: 16365275
[No Abstract] [Full Text] [Related]
11. Erythrodermic psoriasis successfully treated with efalizumab.
Piccirillo F; Stinco G; Patrone P
Eur J Dermatol; 2008; 18(3):357-8. PubMed ID: 18474483
[No Abstract] [Full Text] [Related]
12. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).
Thielen AM; Barde C; Saurat JH
Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444
[No Abstract] [Full Text] [Related]
13. DRESS syndrome caused by efalizumab.
White JM; Smith CH; Robson A; Ash G; Barker JN
Clin Exp Dermatol; 2008 Jan; 33(1):50-2. PubMed ID: 18021270
[TBL] [Abstract][Full Text] [Related]
14. [Efalizumab--therapy of moderately severe to severe plaque-psoriasis in the dermatologist's practice].
Dirschka T; Reinhold U; Rosenbach T; Schubert E; Sebastian M; Streit V
J Dtsch Dermatol Ges; 2006 Oct; 4 Suppl 1():S3-S12. PubMed ID: 17022742
[TBL] [Abstract][Full Text] [Related]
15. Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases.
Antonucci A; Bardazzi F; Balestri R; Patrizi A
J Dermatolog Treat; 2009; 20(1):61-2. PubMed ID: 18618361
[TBL] [Abstract][Full Text] [Related]
16. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
Puig L; Roé E; García-Navarro X; Corella F; Alomar A
Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
[TBL] [Abstract][Full Text] [Related]
17. Long-term management of erythrodermic psoriasis with anti-TNF agents.
Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
[TBL] [Abstract][Full Text] [Related]
18. Infliximab rescue of efalizumab withdrawal flare and psoriasis-precipitated depression.
Yip L; Harrison S; Foley P
Australas J Dermatol; 2008 Nov; 49(4):250-1. PubMed ID: 18855796
[No Abstract] [Full Text] [Related]
19. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
Maskatia ZK; Koo J
J Drugs Dermatol; 2007 Sep; 6(9):941-4. PubMed ID: 17941368
[TBL] [Abstract][Full Text] [Related]
20. [Clinical experience with efalizumab in the Hospital of Cruces].
Martínez de Lagrán Z; González Hermosa MR; Díaz-Pérez JL
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():74-81. PubMed ID: 18341856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
